Key result
Mitral valve repair for functional mitral regurgitation in idiopathic dilated cardiomyopathy was associated with 5.6% in-hospital mortality and 69% actuarial survival at 6.5 years.
Why the study?
Does mitral valve repair improve survival and symptoms in patients with idiopathic dilated cardiomyopathy and severe functional mitral regurgitation?
Observational (n=54)
Does mitral valve repair improve survival and symptoms in patients with idiopathic dilated cardiomyopathy and severe functional mitral regurgitation?
Mitral valve repair for severe functional mitral regurgitation in idiopathic dilated cardiomyopathy is associated with acceptable long-term survival and reverse remodeling, particularly when combined with successful AF ablation or CRT.
Answers are grounded in this paper and cite their sources.
May support mitral repair feasibility in idiopathic dilated cardiomyopathy; leaves open randomized confirmation of survival benefit.
OBJECTIVES: While the results of mitral repair in ischaemic mitral regurgitation have been repeatedly reported, less data are available about the outcome of surgical repair of functional mitral regurgitation (FMR) in idiopathic dilated cardiomyopathy (iDCM) which represents the topic of this study. METHODS: Fifty-four iDCM patients (mean age 63 ± 10.5 years) underwent mitral valve repair for severe FMR. Coronary angiography confirmed the absence of coronary disease in all patients. Most of the patients (77.7%) were in New York Heart Association (NYHA) class III-IV. Pre-operative ejection fraction (EF) was 30.4 ± 8.5%, left ventricle end-diastolic diameter (LVEDD) 67.5 ± 7.8 mm, left ventricle end-systolic diameter (LVESD) diameter 53.9 ± 8.3 mm. Concomitant procedures were atrial fibrillation (AF) ablation (19 patients) and tricuspid repair (17 patients). Follow-up was 100% complete (mean 4.2 ± 2.5 years, median 4.2 years, range 3.3 months-11.1 years). RESULTS: In-hospital mortality was 5.6%. Actuarial survival at 6.5 years was 69 ± 8.8%. Patients submitted to successful AF ablation and/or cardiac resynchronization therapy (CRT) had a significantly better survival (91 ± 7.9 vs 67 ± 9.5%, P = 0.01). Freedom from MR≥3+/4+ was 89.1 ± 5.7% at 6.5 years. Follow-up echocardiography showed a reduction in LVEDD (P < 0.0001) and LVESD (P = 0.0003). Mean EF increased to 38.7 ± 12.4% (P < 0.0001). Multivariate analysis identified successful ablation of AF and/or CRT (P = 0.01) and higher preoperative EF (0.03) as predictors of overall survival. Successful ablation of AF and/or CRT (P = 0.02) and lower preoperative systolic pulmonary artery pressure (0.04) were identified as independent predictors of reverse LV remodelling at follow-up. At last follow-up, 86.2% of the patients were in NYHA II or less. CONCLUSIONS: Mitral repair for FMR in well-selected iDCM patients is associated with low hospital mortality and significant clinical benefit at late follow-up. Concomitant successful AF ablation and/or CRT provide a major symptomatic and prognostic advantage and should be associated to mitral surgery whenever indicated.
No takes yet. Share an insight, caveat, or question.
Bonis et al. (2012) conducted an observational in Functional mitral regurgitation in idiopathic dilated cardiomyopathy (n=54). Mitral valve repair was evaluated on Actuarial survival at 6.5 years. Mitral valve repair for functional mitral regurgitation in idiopathic dilated cardiomyopathy was associated with 5.6% in-hospital mortality and 69% actuarial survival at 6.5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: